News FDA declines to approve AbbVie's Botox follow-up AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Views & Analysis Ipsen’s John Chaddock on making neurotoxins a priority for h... Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get the attention it needs. Ipsen’s John Chaddock tells u
News Lilly strikes $1.9bn kidney disease alliance with Ascidian In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
